Compounds > pyrazolanthrone

Page last updated: 2024-08-18

pyrazolanthrone and tretinoin

pyrazolanthrone has been researched along with tretinoin in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Cho, JW; Choi, WS; Eom, DS; Ji, S; Oh, YJ	1
Chang, DM; Ho, LJ; Hou, TY; Hung, LF; Lai, JH; Liang, CC; Lin, LC; Wang, SJ	1
Bell, JC; Keeney, DS; Strobel, HW; Wang, Y	1

Other Studies

6 other study(ies) available for pyrazolanthrone and tretinoin

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nature chemical biology, 2009, Volume: 5, Issue:10 Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Activation of c-Jun N-terminal kinase is required for neurite outgrowth of dopaminergic neuronal cells. Neuroreport, 2005, May-31, Volume: 16, Issue:8 Topics: Analysis of Variance; Animals; Anthracenes; Blotting, Western; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Mammalian; Enzyme Activation; Enzyme Inhibitors; Hybridomas; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mesencephalon; Mice; Mitogen-Activated Protein Kinases; Neurites; Neurons; Rats; Time Factors; Transfection; Tretinoin; Tyrosine 3-Monooxygenase	2005
Retinoid acid inhibits IL-1-induced iNOS, COX-2 and chemokine production in human chondrocytes. Immunological investigations, 2008, Volume: 37, Issue:7 Topics: Anthracenes; Cell Line; Chemokines; Chondrocytes; Cyclooxygenase 2; Dinoprostone; Humans; Interleukin-1; MAP Kinase Kinase 4; Nitric Oxide Synthase Type II; Transcription Factor AP-1; Tretinoin	2008
Gene regulation of CYP4F11 in human keratinocyte HaCaT cells. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:1 Topics: Alitretinoin; Anthracenes; Benzoates; Cell Line; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 4; Gene Expression; Gene Expression Regulation; Humans; Interleukin-1alpha; JNK Mitogen-Activated Protein Kinases; Keratinocytes; Nicotinic Acids; Phosphorylation; Protein Kinase Inhibitors; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Retinoid X Receptor beta; Retinoids; Signal Transduction; Tetrahydronaphthalenes; Tretinoin; Tumor Necrosis Factor-alpha	2010